Aspen Pharmacare

This page shows the latest Aspen Pharmacare news and features for those working in and with pharma, biotech and healthcare.

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing. Amid reports of price increases of several hundred per cent. ... Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid

Latest news

GSK sells another chunk of South Africa's Aspen

GSK sells another chunk of South Africa's Aspen. Paid $418m for an 18% share in Aspen in 2009. ... GlaxoSmithKline (GSK) has cashed in part of its holding in South Africa's Aspen Pharmacare, raising cash to help fund the ongoing restructuring of its
Publicis boosts South Africa presence

The agency has 80 staff and works with blue-chip clients such as Aspen Pharmacare, Tanqueray Gin and TOTAL.
GSK cashes in its stake in Africa's Aspen

GlaxoSmithKline (GSK) has agreed to reduce its stake in Aspen Pharmacare but says it will maintain a "close relationship" with the South African company. ... Aspen's shares dipped nearly 4 per cent on news of the divestment.
GSK sells Lucozade and Ribena for £1.35bn

it offloaded several other products to to Aspen Pharmacare for £164m.
Pharma deals during August 2012

As Aspen is the major generic player in Australia this represents a viable generics strategy for GSK in this market. ... 430. GSK / Aspen Pharmacare. Divestment. Divestment of classic brands in Australia.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch table for September 2013

840. GSK / Aspen Pharmacare. Acquisition of assets. 2. Arixtra and Fraxiparine - anti-thrombotic agents.
Pharma deals during September 2013

GSK also received $700m from the sale of two thrombosis drugs (Arixtra and Fraxiparine), to Aspen Pharmacare, South Africa's largest drug maker. ... This agreement provides Aspen with the opportunity to expand into Russia and the CIS.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager – Med Comms – London: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Programme Executive: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

Project Manager, Medical Communications, Oxford: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Medical Writer, e-learning/ training, London: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Project Manager, Medical Communications, London: Excellent Salary

Senior Account Manager – Med Comms – Kent: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Medical Writer: Great salary and bebefits

Scientific Director: Great salary and bebefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Account Manager / Account Director: Great salary and bebefits

Editor – Medical Education Agency – Bucks: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Subscribe to our email news alerts

No results were found

PMHub

Add my company

HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...